R&G PharmaStudies Management
Management criteria checks 0/4
We currently do not have sufficient information about the CEO.
Key information
David Wu
Chief executive officer
CN¥1.4m
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | no data |
| CEO ownership | n/a |
| Management average tenure | no data |
| Board average tenure | less than a year |
Recent management updates
Recent updates
R&G PharmaStudies' (SZSE:301333) Conservative Accounting Might Explain Soft Earnings
Nov 06
R&G PharmaStudies' (SZSE:301333) Dividend Will Be Reduced To CN¥0.20
Jul 01Is There An Opportunity With R&G PharmaStudies Co., Ltd.'s (SZSE:301333) 27% Undervaluation?
Jun 06Shareholders Will Be Pleased With The Quality of R&G PharmaStudies' (SZSE:301333) Earnings
Apr 29CEO
David Wu (63 yo)
no data
Tenure
CN¥1,436,800
Compensation
Mr. Wu Jie, also known as David, MBA serves as Chairman and General manager of R&G PharmaStudies Co., Ltd. He served as General Manager and Director of Tianfa Petroleum Co., Ltd.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & GM | no data | CN¥1.44m | no data | |
| COO, Senior VP & Director | no data | CN¥680.80k | no data | |
| Deputy GM & Director | no data | CN¥832.00k | no data | |
| Senior VP | no data | CN¥567.50k | no data | |
| Independent Director | less than a year | no data | no data | |
| Director | no data | no data | 12.15% CN¥ 685.5m | |
| Supervisor | no data | no data | no data | |
| Supervisory Board Chairman | no data | no data | no data | |
| Supervisor | no data | no data | no data | |
| Director | no data | no data | no data | |
| Independent Director | less than a year | no data | no data | |
| Independent Director | less than a year | no data | no data |
0.5yrs
Average Tenure
55yo
Average Age
Experienced Board: 301333's board of directors are not considered experienced ( 0.5 years average tenure), which suggests a new board.